Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01547494
Other study ID # WCCR-MIG1
Secondary ID
Status Completed
Phase N/A
First received February 27, 2012
Last updated May 13, 2013
Start date September 2011
Est. completion date October 2012

Study information

Verified date May 2013
Source Physicians Committee for Responsible Medicine
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess whether, in individuals with migraines, a low-fat, vegan diet improves pain more effectively than a control supplement or a placebo. The principal measures are pain as measured by Visual Analog Scale (VAS) and the change in migraines frequency. The study duration is 36 weeks.


Description:

Preliminary evidence suggests that low-fat, vegetarian diets and certain nutritional supplements can help reduce pain and also reduce the need for pain medications for some people. We will ask about 100 people to participate. All of them will get a low-fat, vegan diet and a nutritional supplement (mixture of omega-3 oils and vitamin E or a placebo), although some will get the diet first, and others will get the supplement first. This order in which they will get the diet and the supplement will be determined randomly, that is, by chance (like the toss of a coin). The principal measures are pain as measured by Visual Analog Scale (VAS)and the change in migraines frequency.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. A diagnosis of migraine, as defined by the criteria of the second edition of the International Classification of Headache Disorders18

- At least 5 attacks fulfilling criteria the criteria below

- Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)

- Headache has at least two of the following characteristics:

- unilateral location

- pulsating quality

- moderate or severe pain intensity

- aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)

- During headache at least one of the following:

- nausea and/or vomiting

- photophobia and phonophobia

- Not attributed to another disorder

2. Migraines occurring at least twice per month, on average.

3. Age at least 18 years

4. Ability and willingness to participate in all components of the study

5. Willingness to be assigned to either the diet group or supplement group

6. Migraine medications unchanged within last 6 weeks.

Exclusion Criteria:

1. < 18 years of age

2. Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use

3. Use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion)

4. Pregnancy

5. Unstable medical or psychiatric illness

6. Likely to be disruptive in group sessions (as determined by research staff)

7. Already following a low-fat, vegan diet

8. Lack of English fluency

9. Inability to maintain current medication regimen

10. Inability or unwillingness to participate in all components of the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Other:
Vegan Diet
Vegan diet, which is devoid of animal products and minimal in fat
Dietary Supplement:
mixture of omega3 and vitamins
mixture of omega3 and vitamins

Locations

Country Name City State
United States Physicians Committee for Responsible Medicine Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Physicians Committee for Responsible Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Migraines Pain Change in Migraines frequency Pain as measured by VAS score Baseline and 4 months No
Primary Change in Migraines frequency the reduction in the number of migraine attacks. Baseline and 4 months No
Secondary Quality of life Health related quality of life as measured by a questionnaire Baseline and 4 months No
See also
  Status Clinical Trial Phase
Recruiting NCT06022848 - Quantitative Sensory Testing and Occipital Nerve Stimulator N/A
Completed NCT01699009 - A Nutritional Intervention for Migraines-2 N/A
Completed NCT01813669 - Integrative Coping Group for Children N/A
Completed NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Terminated NCT04201080 - A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250 Phase 1
Completed NCT00727974 - Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines
Completed NCT00700128 - Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals N/A
Completed NCT00195754 - A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488. Phase 3
Completed NCT01807234 - Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine Phase 4
Completed NCT02748577 - Pain Processing in Adults With Migraines N/A
Completed NCT00753493 - Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients Phase 1
Completed NCT00483704 - Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) Phase 3
Completed NCT01337596 - A Study of LY2951742 in Healthy Volunteers Phase 1